ProShare Advisors
CADX

ProShare Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

ProShare Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-42,358
Closed -$383K – 2735
2013
Q4 		$383K Sell
42,358
-26,836
-39% -$194K 0.01% 1106
2013
Q3 		$437K Buy
69,194
+13,696
+25% +$87.1K 0.01% 1590
2013
Q2 		$378K Buy
+55,498
New +$387K 0.01% 1537

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ProShare Advisors's CADX Position: Q1 2014 in Review

ProShare Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 42,358 shares — an estimated $383K sold.

ProShare Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $437K in Q3 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • ProShare Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • ProShare Advisors sold 42,358 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $383K.
  • ProShare Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • ProShare Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $437K in Q3 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on ProShare Advisors's 13F filing for Q1 2014, filed 7 May 2014.